SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Innate Pharma To Hold Its Annual General Meeting Of Shareholders On June 23, 2017 May 22, 2017 Can-Fite BioPharma Reports Second Quarter 2017 Financial Results & Provides Clinical Update August 31, 2017 <b>ZEISS</b> Unveils Ultra-Widefield Fundus Imaging Technology In U.S. September 14, 2017
Can-Fite BioPharma Reports Second Quarter 2017 Financial Results & Provides Clinical Update August 31, 2017
